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Introduction 
The Royal College of Physician’s report ‘Underfunded, Underdoctored and Overstretched’ 
gives a bleak picture of the current state of the National Health Service (NHS)(1). Currently 
healthcare and the NHS accounts for the second largest spend area for government, reaching 
£116.4 billion in 2015/16. Despite this, however, in 2015, prior to the Brexit referendum, 
hospitals recorded a deficit of £2.45 billion(2).  
This deficit is on a background of rising clinical demand with a growing ageing population, 
social care funding being cut and medicines and health technologies increasing in cost. The 
gap between clinical need and available resources is widening. One key aspect of the Vote 
Leave campaign’s argument was that £350 million a week could be saved, from UK 
contributions to the EU, which could be spent on the NHS(3). This promise, however, was 
disowned immediately after the referendum. 
Any change in the UK’s economy could lead to NHS funding being affected or in the words of 
Simon Stevens, NHS CEO ‘When the economy sneezes, the NHS catches a cold’(4). While the 
latest figures show that the economy grew by 0.6% between July and September 2016(5) 
there is significant uncertainty in the longer-term. The Bank of England has recently revised 
its forecast for economic growth to 2 percent for 2017, a significant increase from its previous 
forecast of 1.4 percent(6).  
Despite the White Paper on the UK’s exit from, and new partnership with, the EU published 
on 2nd February(7), there is still a large degree of uncertainty on what Great Britain’s future 
out of the EU will look like. Several of the principles that the Prime Minister set out are likely 
to have a significant impact on the UK’s health and social care system if they come to pass.  
We discuss the potential impact, both positive and negative, that these principles may have 
on the NHS in four key areas of workforce, regulations, cross-border cooperation and research 
and innovation. 
Workforce 
There is already a shortage of healthcare staff in the NHS. The UK has 278 doctors per 100,000 
compared with an EU average of 347 per 100,000(8). Seven out of ten doctors-in-training in 
the UK report working on a rota with a permanent gap and hospitals are failing to fill two out 
of every five consultant posts that they advertise(1, 9). Four out of five doctors-in-training 
report that their job causes them excessive stress and 95% report that poor staff morale has 
a negative impact on patient safety in their hospital(1). This has contributed to ‘home-grown’ 
doctors leaving the NHS, in part due to lack of motivation. Furthermore statistics from the 
Nursing and Midwifery Council (NMC) showed that there are 24,000 nursing vacancies across 
the NHS(10). Fewer nurses are being trained at UK universities following the government’s 
announcement that new nursing, midwifery and allied health professional students would no 
longer have their fees paid for by Health Education England or be eligible for bursaries to 
support their living costs(11). Bursaries will be replaced by loans.   
The NHS Confederation reports that there are approximately 144,000 EU health and care 
workers in England(12). The GMC currently has over 30,000 doctors registered who gained 
their primary medical qualification from another country in the European Economic Area 
(EEA) – this is about 11% of 280,000 doctors currently on the register(13).  
The above evidence suggests that the current levels of staffing in the NHS are inadequate. If 
a ‘hard’ Brexit is to be followed with no access to the single market and limits to immigration, 
as recommended by the Prime Minister, this may negatively impact the numbers of staff. 
While the recent White Paper does aim to ‘protect and enhance the rights people have at 
work’, there is no guarantee as to whether the EU workers currently resident will be allowed 
to stay(7).   
The Free Movement Directive sets out the rights of EU citizens and their family members to 
move and reside freely within the territory of the EU and in the UK this will cease to apply 
following Brexit(14). In the short-term EU staff may be deterred from coming to, and/or 
staying in, the UK due to the uncertainty over employment rights. The number of EU nurses 
coming to the UK has reportedly fallen by 90% since the vote and the statistics also show a 
rise in the number of EU nurses who have decided to stop working in the UK. In December, 
318 decided to leave the NMC’s register – almost twice the 177 who did so the month before 
the referendum, although it is perhaps too early to say whether a trend will emerge(10).   
In the longer-term an immigration system will be designed to control the numbers of people 
coming from the EU(7). This immigration system must be capable of attracting both highly 
skilled and less skilled workers for the health and social care sector. After the Referendum the 
Cavendish Coalition was created, a coalition of 33 health and social care organisations aiming 
to ensure sustainable workforce supply and maintaining standards of care as Britain 
withdraws from the EU(15). The group acts as a shared voice aiming to influence and lobby 
on post-EU referendum issues that affect the health and social care workforce as well as 
ensuring a robust evidence base to support workforce policy.  
  
The Secretary of State for Health has pledged £100 million to fund an extra 1,500 medical 
student places from 2018 in an effort to make the NHS ‘self-sufficient’ in doctors by the end 
of next parliament(16, 17). Despite this promise, it is likely that, at least in the short term, the 
UK will still be reliant on foreign-trained doctors given the long training times of medical 
students. Furthermore, at the amount the government says that it costs the taxpayer to train 
a doctor (over £200,000) this promise would cost at least £330 million rather than £100 
million(18). 
  
Regulations 
One of the Prime Minister’s principles set out in the White Paper includes ending the 
jurisdiction of the Court of Justice of the European Union in the UK, meaning that UK’s laws 
will be made in London, Edinburgh, Cardiff and Belfast. Many national health activities are 
currently subject to EU law and policy(19) and a number of different regulations are likely to 
be impacted, some of which are set out below. The Great Repeal Bill, announced to the UK 
Parliament on 10 October 2016, will preserve EU law where it currently stands, enabling 
Parliament to decide which elements of the law to keep, amend or repeal once the UK has left 
the EU(7).  
The EU’s Working Time Directive (EWTD) aims to protect workers’ health and safety by 
ensuring that working hours meet minimum standards applicable throughout the EU. The 
Working Time Directive was applied to the majority of workers in the UK in 1998, and by 
August 2011 all junior doctors’ working hours had to comply with the 48-hour requirement 
averaged over 6 months.  
There are differing views within the healthcare system, and the wider workplace, as to the 
utility of this directive. The British Medical Association (BMA) has reported satisfaction with 
the EWTD and the reduction in maximum hours worked. In 2014 the EWTD Taskforce 
concluded that the Working Time Directive has had an adverse impact in the NHS on training 
in certain medical specialties including surgeons and doctors working in acute medicine 
specialties(20). This is because it introduced an inflexibility into working patterns, with a move 
towards shift work and away from the firm structure, which has impacted on the quality of 
training and continuity of care. Exiting the EU may allow the UK greater flexibility to set its 
own employment regulations. 
The UK currently has to abide by the EU’s Directive on the Recognition of Professional 
Qualifications and the GMC has argued that Brexit presents the opportunity for regulators to 
test the competence of European health professionals, like they do for non-EU international 
professionals, with rigorous assessments of their knowledge and clinical skills(13). This would 
provide the UK with an opportunity to review and agree minimum training requirements for 
medicine that most suit UK healthcare needs while continuing to meet GMC standards.  
Another critical implication of leaving the EU single market is that the UK will no longer be 
part of the European Medicines Agency (EMA). The EMA is responsible for the scientific 
evaluation, supervision and safety monitoring of human and veterinary medicines developed 
by pharmaceutical companies for use in the EU and is currently based in London. A number of 
EU states have already expressed interest in hosting the EMA. Member countries have access 
to a single marketing authorization, meaning that pharmaceutical companies only have to go 
through one approval process before launching their drugs throughout Europe(21). Loss of 
access to the single authorization may lead to extra regulatory hurdles for drug companies 
and ultimately a delay in access to new medicines, although alternative solutions may be 
devised which limit this delay. The UK’s Medicines and Healthcare Products Regulatory Agency 
(MRHA) and the EMA may be able to develop mutual recognition agreements and the 
government should seek to maintain the best possible form of cooperation. Given the likely 
change in the US regulatory system with the Trump presidency, it is currently uncertain how 
the FDA, EMA and the MRHA will align. 
It is likely that Brexit will have a limited impact on NHS procurement and competition 
regulation. Newly negotiated trade agreements with other countries, including in Europe, is 
likely to result in public sector procurement rules for the UK broadly similar to what is 
currently in place(22). NHS competition rules have three main components: the prohibition 
on anticompetitive behaviour, merger control and the prohibition on illegal state aid. With 
regards to competition rules, exiting the EU may make it easier to lift the current prohibition 
on anticompetitive behaviour by NHS providers and commissioners, if this was desired(22). 
The EU plays a significant role in public health. One of many areas of importance includes the 
early warning and response system for the prevention and control of communicable diseases 
of which the European Centre for Disease Control and Prevention (ECDC) is at the centre(23, 
24). This system allows for information sharing and coordination of response at the EU level 
to cross-border health threats and there is uncertainty over the UK’s role in this, and other 
European agencies such as the Directorate General for Health and Food Safety, after exiting 
the EU. 
Cross-border cooperation 
Approximately 1 million UK citizens reside in the EU and are currently entitled to healthcare 
as local residents under the S1 scheme(25). Reciprocal rules means that EU nationals have the 
same rights to receive healthcare in the UK. Currently many more expat UK pensioners rely 
on European healthcare than UK-based European pensioners rely on the NHS. Across the EEA 
there are about 145,000 UK expat pensioners registered compared with 4,000 EEA pensioners 
registered to use the NHS(26). The Department of Health (DH) figures show that the UK and 
Spain have the biggest disparity in numbers of pensioners covered by the reciprocal 
healthcare agreement as of December 2016. While ‘Securing the status of, and providing 
certainty to, EU nationals already in the UK and to UK nationals in the EU is one of this 
Government’s early priorities for the forthcoming negotiations’, it is not clear if this will be 
possible. 
European Health Insurance Cards (EHIC) give British citizens the right to state-provided 
healthcare during a temporary stay in another EU or EEA country. By removing the EHIC, the 
costs will shift directly to the patients. It is estimated that UK travellers to the EU have saved 
around £1.2 billion since the EHIC scheme began in 2006(27). Without this it is feared that the 
cost of travel insurance will rise as insurers find themselves liable for medical treatment that 
is currently free of charge. The Secretary of State for Health gave no guarantee in his talk to 
the Health Committee that these would remain on withdrawal from the EU(28).  
After exiting the EU it is unlikely the UK will be able to keep either the S1 or EHIC schemes as 
they form part of the EU’s Social Security Coordination programme and leaving the single 
market is likely to keep the UK outside these rules. While in theory there is nothing to prevent 
the UK developing 30 new deals to replicate these schemes, in practice this would be 
challenging.  
Research and Innovation  
The UK has been a net beneficiary of EU health research funds, mostly from the Horizon 2020 
programme, and there is a concern that with a hard Brexit the UK will lose access to the 
funding, but also the talented scientists and researchers from the EU. On a positive note, the 
UK government has guaranteed to underwrite funding of approved Horizon 2020 grants 
applied for before the UK leaves the EU, even when projects continue beyond the UK’s 
departure from the EU(29). The aim of the guarantee was to help reassure partner institutions 
in other EU countries that have raised concerns about whether to continue to collaborate with 
UK institutions on EU funding bids. There remains uncertainty in the longer term, however, as 
to whether UK scientists may lose the ability to apply for EU funding once Brexit occurs.  
Alongside research funding, access to EU infrastructures and networks, such as CERN and 
clinical trials networks, encourages innovation and also enhances the UK’s global influence(3). 
Investing in science, research and innovation has been made a priority in the recent Industrial 
Strategy Green Paper and the Prime Minister has made a point in her 12 principles that they 
will try to ensure that Great Britain remains the best place for science and innovation(7, 30). 
It is crucial that there is continuing UK participation in mutually beneficial European 
collaborations in medical research and innovation. 
What can be done? 
During the negotiations, all rights and obligations from EU membership will continue as 
normal, but after this it is in the interests of both the UK and the EU to come to mutually 
beneficial agreements. While the implications of Brexit are far broader than the scope of this 
paper, this has analysed the possible impacts in the areas of the health and social care 
workforce, regulations, cross-border cooperation and research and innovation. 
It is clear that the health and social care workforce is in crisis with significant deficits across 
the board. The priority must be on safeguarding those EU citizens currently working here but 
also designing an immigration system which will attract both highly skilled and less skilled 
workers to the NHS. 
With the announcement of the Great Repeal Bill, the UK government is in a position to 
continue to follow EU law and maintain existing regulatory frameworks and standards where 
these work well or enable significant changes to a number of regulations which could work to 
the advantage of the NHS. 
For the benefit of UK citizens and citizens of EU and EEA countries, it is essential that a 
mutually beneficial agreement is made in regards to the S1 and EHIC schemes. It is the 
pensioners and travellers that will suffer in the face of changes on both sides of the Channel.  
International collaboration is key to furthering scientific research and rightly this has been 
made a priority in the recent White Paper(7). Continued access to collaboration with talented 
scientists in the UK and EU, access to clinical trials networks and coordinated responses to 
cross-border health threats is again mutually beneficial to staying at the cutting edge of 
science and fighting global battles such as antimicrobial resistance.  
There is no doubt that the world is in a time of great uncertainty but it is important to work 
towards the most positive impact of Brexit for both the UK, the EU, and the rest of the world.  
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